ArticleProceedings of the National Academy of Sciences of the United States of America2026
FUT1- and GAL3ST2-mediated cellular glycan remodeling broadly restricts sialic acid-dependent viral infections.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Novel Cell-Based High-Throughput Screening Model for Inhibitors Targeting Influenza Virus Hemagglutinin-α-2,6-Sialic Acid Interaction.Biomolecules · 2026Article
- Fucosyltransferases in asthma: regulators of epithelial dysfunction, senescence, and airway inflammation.Clinical reviews in allergy & immunology · 2026Review
- α2-3-Sialylated Glycoproteins AttenuateInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Sialic acid is an abundant terminal glycan found on the surface of almost all mammalian cells and is utilized by many viruses as an attachment factor and/or bona fide receptor. Altering canonical cellular glycosylation can affect the ability of viruses to initiate infections; however, no systematic analysis of the effects of altering expression of glycan "capping" enzymes on viral infection rates has been previously performed. We therefore designed an arrayed CRISPR activation screen that targeted 54 glycosyltransferases known to perform terminal glycan modifications and then examined the susceptibility of 12 different viruses that rely on sialic acid receptors on the resultant cell lines. We identified two glycosyltransferases, fucosyltransferase 1 (FUT1) and galactose-3-O-sulfotransferase 2 (GAL3ST2), as capable of inhibiting a broad range of viruses when upregulated, including influenza viruses, respiroviruses, paramyxoviruses, enteroviruses, and coronaviruses. Lectin and viral particle binding assays revealed that the fucosylation and sulfation mediated by FUT1 and GAL3ST2 reduced availability of cell surface expressed α2-3 and α2-6 sialylation and impaired viral attachment during the initial entry process. Furthermore, through adeno-associated virus delivery, we confirmed the inhibitory effects of FUT1 and GAL3ST2 on influenza viruses in various cell models, including primary differentiated human airway cells. Together, our findings identify FUT1 and GAL3ST2 as host restriction factors and suggest that their therapeutic dysregulation may represent a broad-spectrum antiviral strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.